LIGHT Detection Set (Risk Free)

LIGHT Antibody: LIGHT, also known as Tumor Necrosis Factor Superfamily member 14 (TNFSF14), is a co-stimulatory molecule that can regulate T-cell activation (1) and has recently been identified as an immune checkpoint protein. LIGHT binds to two different receptors, Herpes Virus Entry Mediator (HVEM) and Lymphotoxin beta Receptor (LTβR) . While LIGHT binding to HVEM delivers a co-stimulatory signal to T cells (1), LIGHT binding to LTβR is critical for the formation of lymphoid structures which can stimulate T cell infiltration and activation of a tumor microenvironment, leading to rapid T cell-mediated tissue destruction (2) . It has been shown that targeted delivery of LIGHT to tumors, thereby causing the T cell infiltration of the tumor, can enhance the response of the PD-1/PD-L1 checkpoint blockade anti-cancer therapy (3), suggesting that LIGHT may become a potent tool in anti-cancer treatment. ProSci's Risk-FreeTM antibodies are mouse monoclonal antibodies made to improve in vivo studies. Unlike antibodies developed using proteins made in yeast or bacteria, Risk-FreeTM antibodies are developed with antigens expressed in mammalian cell lines, giving the most native post-translational modifications to the protein. Validated for flow cytometry and ELISA Rigorously tested for the following applications: Immunoblot Immunohistochemistry Immunocytochemistry Immunofluorescence Multiple antibodies per target allowing the user to choose the best antibody for their application Available individually or as a set Risk-FreeTM means they are guaranteed to work for their approved applications

Lee Y, Chin RK, Christiansen P, et al. Recruitment and activation of naive T cells in the islets by lymphotoxin beta receptor-dependent tertiary lymphoid structure. Immunity 2006; 25:499-509.

Tang H, Wang Y, Chlewicki LK, et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 2016; 29:285-296.